BioSpace News Archive

Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today provided a further update with respect to the cancellation of admission of its Ordinary Shares to trading on AIM and the continued listing of its ADSs on Nasdaq, as originally announced on November 11, 2020.

Coverage includes Pfizer/BioNTech vaccine and any other COVID-19 vaccines that receive emergency use authorization from the FDA (including Moderna’s mRNA-1273)

MYOS CORP (“MYOS” or the “Company”), is a research-based advanced nutrition company with divisions that address both Human Nutrition and Animal Health . MYOS is the sole owner of Fortetropin ® , a proprietary advanced nutrition product developed and owned by MYOS, that has been shown in multiple veterinary and human cli

This week, Health Canada and Statistics Canada released new results from the biomonitoring component of the Canadian Health Measures Survey.

Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced publication of the results from a pivotal, phase 3 trial, which showed that SECUADO® (asenapine) transdermal system demonstrated significant improvement in Positive and Negative Syndrome Scale (PANSS) total score at Week 6 versus placebo in adult patients with schizophrenia.

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that it intends to offer and sell, subject to market and other conditions, 2,250,000 shares of its common stock in an underwritten public offering

Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, today reported positive six-month follow-up data from the low-dose cohort (1.5x1013 vg/kg) of the Company’s dose escalation study of AXO-AAV-GM1, its adeno-associated viral vector (AAV)9-based gene therapy candidate for the treatment of GM1 gangliosidosis.

4D Molecular Therapeutics, Inc. (4DMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced today the closing of its initial public offering of 9,660,000 shares of its common stock, including 1,260,000 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a price of $23.00 per share

Rhythmlink International, LLC is pleased to announce an exciting new investment, the acquisition of Chalgren Enterprises, a California-based medical device manufacturer that will add to their already extensive portfolio of products for brain and nervous system monitoring.

9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the a clinical-stage rare and unmet needs-focused gastroenterology company, announced today the closing of its previously announced underwritten public offering of 53,076,924 shares of its common stock